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Highlights 
•Enzalutamide and abiraterone prolong OS, but resistance is a major clinical problem. 
•Mechanisms of de novo or acquired resistance can be AR-dependent or AR-independent. 
•To prevent or overcome resistance, many new agents are currently being tested. 
•The addition of these drugs may improve synergically the efficacy of hormonal therapy. 
 
Abstract 
In recent years, in castration resistant prostate cancer (CRPC), several new drugs have been approved that 
prolong overall survival, including enzalutamide and abiraterone, two new-generation hormonal 
therapies. 
Despite the demonstrated benefit of these agents, not all patients with CRPC are responsive to treatment, 
the gain in median progression-free survival with these therapies compared to standard of care is, rather 
disappointingly, still less than six months and the appearance of acquired resistance is almost universal. 
Approximately one third of patients treated with abiraterone and 25% of those treated with enzalutamide 
show primary resistance to these agents. Even if the mechanisms of resistance to these agents are not 
fully defined, many hypotheses are emerging, including systemic and intratumoral androgen biosynthesis 
up-regulation, androgen receptor (AR) gene mutations and amplifications, alteration of pathways involved 
in cross-talk with AR signaling, glucocorticoid receptor overexpression, neuroendocrine differentiation, 
immune system deregulation and others. 
The aim of this paper is to review currently available data about mechanisms of resistance to abiraterone 
and enzalutamide, and to discuss how these mechanisms could be potentially overcome through novel 
therapeutic agents. 
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Introduction 
With nearly 220,000 new cases expected in the USA in 2015, prostate cancer (PC) represents the most 
frequent type of cancer in men, accounting for almost 26% of new cancer cases [1]. Despite most of the 
new patients are diagnosed in early stage, approximately 4% of the cases at baseline are in advanced 
stage and some patients treated initially with radical surgery will subsequently relapse. 
Since the seminal work of Huggins and Hodges [2], androgen deprivation therapy (ADT), either surgical or 
biochemical, has been the mainstay of treatment for relapsed and metastatic PC patients, due to the 
driving role of androgen receptor (AR) in the development of these tumors. 
Despite the initial high response rates, many patients become castrate-resistant within 3 years from the 
start of ADT and, consequently, there is a growing interest in testing new agents and strategies to 
overcome acquired resistance. 
Recently it has been shown that, in castration resistant PC (CRPC) patients, even small concentrations of 
extra-gonadal androgens persisting despite ADT could activate the AR pathway and that PC cells could 
synthesize their own androgens [3]. Following these observations, a renewed interest on the AR signaling 
pathway was generated, and a second generation of hormonal therapies has been developed. 
Abiraterone acetate is an oral drug that selectively and irreversibly inhibits the CYP17A1 microsomal 
enzyme, leading to the inhibition of testosterone biosynthesis in adrenal glands, in testis and in PC cells. 
Enzalutamide is an oral AR antagonist with an 8-fold higher affinity for its target than bicalutamide, 
preventing also AR nuclear translocation and DNA binding. 
In CRPC, patients pretreated with docetaxel, two phase III trials, COU-AA-301 and AFFIRM, showed an 
improvement in overall survival (OS) with abiraterone (median OS 14.8 vs 10.9 months; hazard ratio [HR] 
0.65, 95% CI, 0.54–0.77; p < 0.001) [4] and enzalutamide (median OS 18.4 vs 13.6 months; HR 0.63, 95% 
CI, 0.53–0.75; p < 0.001) [5], respectively. More recently, the COU-AA-302 study confirmed the efficacy of 
abiraterone in asymptomatic and mildly symptomatic chemotherapy-naive metastatic CRPC patients in 
terms of OS (median OS 34.7 vs 30.3 months; HR: 0.81, 95% CI, 0.70–0.93; p = 0.0033) [6]. 
In the PREVAIL study, enzalutamide showed a statistically significant 29% reduction in the risk of death 
(HR 0.70, 95% CI, 0.59–0.83; p = 0.0001) and an 81% reduction in the risk of radiographic progression 
compared to placebo (HR 0.19; CI 95%, 0.15–0.23; p < 0.0001) [7]. 
Based on these data, the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) 
granted approval for abiraterone for the treatment of both docetaxel-naive and docetaxel-pretreated 
CRPC patients and for enzalutamide in the post-docetaxel setting. 
Despite the inhibitory properties of these agents, PC cells, even after initial response, become resistant 
and cause clinical disease progression, posing the question how to deal with acquired resistance. In this 
paper we will review the putative mechanisms of primary and acquired resistance to new hormonal 
agents and some potential new strategies to overcome it. 
Physiological androgen synthesis 
In adult men, testosterone (T) and 5-α-dihydrotestosterone (DHT), mainly produced in the testes, with 
only 5–10% being synthesized from the adrenal glands, are the commonest forms of endogenous 
androgens and the major physiological AR ligands. Other steroid hormones, also produced by the adrenal 
glands, such as androstenedione and dehydroepiandrosterone (DHEA), can bind the AR. 
In peripheral tissues, weak adrenal androgens such as DHEA-sulfate (DHEA-S) can be reduced to T, even if 
this biochemical transformation seems to be a negligible source of T in men with intact testes. 
In the adrenal glands and testes, all steroid hormones, including T, are synthesized from cholesterol as 
initial 27-carbon substrate, through sequential reactions catalyzed by several enzymes. 
Pregnenolone is generated from cholesterol and the biochemical reaction is catalyzed by the cholesterol 
side chain cleavage mitochondrial enzyme CYP11A1. The Leydig cells of the testis, the theca and granulosa 
cells of the ovary, the adrenal cortex cells have sufficient CYP11A1 levels to significantly contribute to the 
whole pool of circulating steroids. 
The enzyme 3β-hydroxysteroid dehydrogenase 1 (HSD3B1), expressed in peripheral tissues such as 
prostate basal epithelium and the enzyme 3β-hydroxysteroid dehydrogenase 2 (HSD3B2), expressed in 
steroidogenic organs, are two iso-enzymes responsible for the oxidation of 3β-hydroxy-D
5
-steroids to their 
3-keto-D
4
-congeners. In fact these iso-enzymes isomerize the double bond between C5 and C6 to that 
between C4 and C5, resulting in the specific conversion from pregnenolone to progesterone, from 17-OH-
pregnenolone to 17-OH-progesterone and from DHEA to androstenedione (AD). 
Another enzyme acting on pregnenolone is the 17α-hydroxylase/17,20-lyase (CYP17A1), a microsomal 
enzyme with two functional activities: 17alpha-hydroxylase which catalyzes the 17alpha-hydroxylation of 
C21 steroids and 17,20-lyase which catalyzes C17–21 bond scission, converting C21 compounds to C19 
steroids both in testis and adrenal glands. 
The sequential reactions catalyzed by CYP17A1 result in the synthesis of oxidized (17-keto) androgens 
such as DHEA from pregnenolone and AD from progesterone. In the adrenal glands AD and DHEA are the 
major substrates for aldo–keto reductase 1 (AKR1C3), enzyme responsible for the reduction of AD to T 
and the reduction of DHEA to androstenediol, then converted to T by HSD3B2.A different enzyme, the 17-
β-hydroxy-steroid dehydrogenase type 3 (HSD17B3), mediates T synthesis from DHEA in the Leydig cells of 
the testes. 
The final reaction of the sex steroid synthetic pathway is the 5 α reduction of circulating T to the more 
potent androgen 5 α-dihydrotestosterone (DHT) in genital tissues and prostate, catalyzed by the type 1 
and type 2 isoforms of steroid 5α-reductase (SRD5A1, SRD5A2). This represents the classical pathway of 
androgen biosynthesis. 
DHT synthesis can be obtained, without intermediate T synthesis, through two other pathways: the first 
one called “backdoor pathway”, that consists in eight enzymatic steps and synthesizes androsterone from 
progesterone or 17-OH-progesterone and then synthesizes DHT via 3α-androstanediol production. The 
second is the alternative pathway that leads to DHT synthesis from 5-alpha androstenedione through the 
enzyme AKR1C3 (Fig. 1) [8]. 
 
Fig. 1.  
Physiological androgen synthesis and suggested mechanisms of resistance to enzalutamide and 
abiraterone. (A) Androgen biosynthesis pathways upregulazion, (B) intratumoral de novo steroid 
synthesis, (C) AR mutations, amplification and overexpression, (D) AR slice variants, (E) GR overexpression, 
(F) Co-activators increase and co-repressor decrease, (G) autophagy induction, (H) PD-L1/PD-1 
upregulation. AR: androgen receptor, T: dihydrotestosterone, G: glucocorticoids, GR: glucocorticoids 
receptor 
Figure options 
 
The androgen receptor 
The AR gene is located on chromosome Xq11–12 and accounts for eight exons. AR is a 110-kDa nuclear 
protein that contains 918 acid residues and binds a specific hormone response element (HRE) known as 
androgen response element (ARE). AR is formed by different domains: the N-terminal domain (NTD), the 
DNA-binding domain (DBD), the hinge region and the ligand-binding domain (LBD) [9]. 
Once activated, AR binds AREs as a dimer. There are two different AREs: the inverted repeat AREs, that 
bind and mediate transcriptional activation of both glucocorticoid receptor (GR) and AR, and the direct 
repeat AREs that are specific for AR. Nuclear translocation and DNA-binding properties of AR are also 
enhanced by phosphorylation on NTD [10] and by the interaction with chaperones [11]. 
AR binding with testosterone and DHT results in a conformational change of AR leading to a tight 
homodimeric binding to AREs. Many co-activators and co-repressors modulates this interaction and, at 
the same time, allow a cross-talk with several other pathways involved in cellular signaling and apoptosis 
[12]. 
The adaptive response to androgen deprivation 
Recently, a significant shift in the understanding of natural history of PC has occurred and it is currently 
known that castration resistance does not necessarily results in resistance to hormonal agents. In fact, 
despite the dramatic decrease of serum T induced by ADT, CRPC remains driven by AR signaling, being 
able to overexpress androgen dependent genes [13]. 
Multiple mechanisms have been identified to explain this phenomenon, including AR gene mutation [14], 
AR gene overexpression [15], AR splice variants expression [16], increased expression of transcriptional 
co-activators [14]. 
Intraprostatic synthesis can be a significant source of androgen under the selective pressure of endocrine 
therapy [17]. Several studies showed that intraprostatic androgen levels remain significantly elevated 
despite ADT [18], [19], [20] and [21]. One of these study demonstrated that patients had a 95% reduction 
in T serum levels corresponding only to a 70–80% reduction in intraprostatic T and DHT [21]. Data in 
metastatic CRPC tumor samples showed that tumor progression was associated to the up-regulation of 
steroidogenic enzymes [22] and [23] and intratumoral androgens accumulation [24]. 
PC cells can synthesize androgens through two mechanisms: the first through conversion from androgen 
precursors derived from adrenal glands such as androstenedione, DHEA and DHEA-S [22] and the second 
way is represented from the de novo synthesis from cholesterol [23]. 
The mechanisms of resistance to abiraterone or enzalutamide 
Despite the demonstrated benefits of both abiraterone and enzalutamide, some CRPC patients are 
primary resistant and do not respond to treatment, the gain in progression-free survival and OS obtained 
with these therapies is clinically relevant but limited, and the appearance of acquired resistance is the rule 
for all treated patients. 
Although primary resistance has been defined by some authors as the absence of PSA reduction [25], a 
commonly accepted definition of primary resistance is a treatment failure within the first months (usually 
3) after initiation, as a result of overt clinical progression, with or without imaging progression [26]. 
According to this conventional definition of primary resistance, treatment failures that occur later are 
considered acquired resistance. 
Since a significant proportion of patients treated with enzalutamide and abiraterone showed primary 
resistance, the understanding of the biology of these mechanisms is crucial in order to develop new 
treatment strategies. The percentage of patients with primary resistance in published phase III studies 
with CYP17A1 inhibitors (abiraterone [4] and [6] and orteronel [27] and [28]) and AR inhibitors 
(enzalutamide [5] and [7]), defined as the probability of radiographic progression within the first 
3 months, are reported in Table 1. Several mechanisms of acquired and primary resistance have been 
reported, including systemic and intratumoral androgen biosynthesis up-regulation, AR gene mutations 
and amplifications, alteration of pathways involved in cross-talk with AR signaling, glucocorticoid receptor 
overexpression, neuroendocrine differentiation and immune system deregulation (Table 2). 
Table 1.  
Percentage of patients with primary resistance (defined as probability of radiographic progression within 
the first 3 months) in published phase III studies with abiraterone, enzalutamide and orteronel. 
Study 
Probability of early radiographic progression (within the first 
3 months)⁎ 
 
Experimental arm Control arm 
Chemotherapy-naïve 
Abiraterone plus 
prednisone[6] 
Less than 10% of 
patients 
(Placebo plus prednisone): 
about 20% of patients 
Enzalutamide [7] 
Less than 10% of 
patients 
(Placebo): about 30% of 
patients 
Orteronel plus 
prednisone [28] 
Less than 10% of 
patients 
(Placebo plus prednisone): 
slightly more than 10% of 
patients 
Pretreated with chemotherapy 
Abiraterone plus 
prednisone [4] 
Slightly less than 
40% of patients 
(Placebo plus prednisone): 
slightly less than 50% of 
patients 
Enzalutamide [5] 
Slightly more than 
20% of patients 
(Placebo): about 50% of 
patients 
Orteronel plus 
prednisone [27] 
About 15% of 
patients 
(Placebo plus prednisone): 
about 20% of patients 
⁎ 
Probability of radiographic progression within the first 3 months is estimated from Kaplan–Meier curves 
of radiographic progression-free survival. 
Table options 
Table 2.  
Proposed mechanisms of resistance to abiraterone and enzalutamide. 
Abiraterone Enzalutamide 
AR amplification/overexpression AR amplification/overexpression 
AR mutations AR mutations 
AR activation by exogenous corticosteroids and 
steroid precursors upstream CYP17A1 
AR splice variants 
AR splice variants 
Glucocorticoid receptor 
overexpression 
Androgen biosynthesis pathway upregulation Intracrine synthesis of androgens 
Glucocorticoid receptor overexpression Crosstalk with growth factor 
Intracrine synthesis of androgen Neuroendocrine transformation 
Neuroendocrine transformation Autophagy induction 
Autophagy induction Immune evasion 
Immune evasion 
 
Table options 
Androgen biosynthesis pathway up-regulation and intratumor de novo steroid synthesis 
Studies with CRPC xenografts have shown that several genes involved in the androgen synthesis pathway 
are upregulated during treatment with abiraterone such as a 2-fold overexpression of CYP17A1 gene [29]. 
Studies in animal models have also shown that tumor relapse on abiraterone was associated with further 
upregulation of intratumor CYP17A1 and other key genes involved in intratumor androgen synthesis, such 
as CYP11A1, AKR1C3 and HSD17B3 [30]. 
Abiraterone does not completely ablate serum precursor steroids such as DHEA-S, which in PC cells could 
be transported and metabolized to DHEA by steroid sulfatase. Therefore, tumor cells exposed to 
abiraterone increase their ability to carry in and metabolize steroid precursors downstream of CYP17A1. 
A gain-of-function mutation (N367T) was shown to produce 3 beta-hydroxysteroid dehydrogenase type 1 
resistant to ubiquitination, which results in the accumulation of this enzyme responsible for DHT synthesis 
during treatment with abiraterone [31]. Moreover, DHT can be synthesized from 5-alpha-
androstenedione instead of T through the activity of the enzyme AKR1C3 that is over-expressed in CRPC 
[15]. 
It has been reported that AR activity in the castration resistant VcaP xenografts is driven by CYP17A1 and 
AKR1C3-dependent de novo intratumor androgen synthesis from cholesterol and in tumor biopsies from 
CRPC patients treated with CYP17A1 inhibitor therapy intratumor expression of CYP17A1 was increased. 
CRPC cells expressing a progesterone responsive T878A mutant AR are not CYP17A1-dependent, but AR 
activity in these cells is steroid dependent yet and mediated by upstream CYP11A1-dependent intratumor 
pregnenolone/progesterone synthesis [17]. 
AKR1C3 is overexpressed also in enzalutamide resistant PC cells and this overexpression confers 
resistance to enzalutamide, while down-regulation of AKR1C3 in PC cells induces sensitization to the same 
agent. Moreover indomethacin, a potent AKR1C3 inhibitor, re-sensitizes enzalutamide resistant PC cells to 
enzalutamide both in vivo and in vitro [32]. 
Androgen receptor mutations 
As a consequence of the androgen deprivation and androgen receptor antagonism, clonal selection of 
tumor cells can determine the expansion of both AR somatic mutation and aberrant transcription. The 
frequency of AR mutations, which is about 8–25% in CRPC treated with ADT, may become a even more 
relevant resistance mechanism in the context of more effective suppression of AR signaling. 
Mutations in the AR ligand-binding domain can alter its structure and enable its activation by alternative 
ligands including progesterone, hydrocortisone, estradiol and certain AR antagonists [33]. 
Since serum levels of progesterone and other upstream steroids are increased during treatment with 
CYP17A1 inhibitors mutant AR, that are activated by these upstream steroids, may represent a relevant 
resistance mechanism. A specific AR mutation, L701H (or L701 coupled with T878A) warrants the AR to 
respond to glucocorticoids and progesterone [34] and [35] and CRPC cells expressing this progesterone 
and glucocorticoid responsive T878A mutant AR are resistant to CYP17A1 inhibition [17] and [35]. 
The results of a phase I/II study of abiraterone in chemotherapy-naïve patients support the hypothesis of 
AR activation by other steroids [32]. In that trial, dexamethasone was added at the time of disease 
progression and led to the reversion of resistance in 33% of patients regardless of prior treatment with 
dexamethasone, quite likely related to a reduction of ACTH-mediated stimulation of steroid synthesis. 
However, it should be also taken into account that the exogenous glucocorticoid or mineralocorticoid 
antagonists administered to control abiraterone side effects may contribute to activate mutant AR [34]. 
Studies in PC cell lines treated with enzalutamide and ARN-509 have identified a new missense mutation 
(F876L) in the LBD of the AR, that confers an antagonist-to-agonist switch driving the resistance to 
enzalutamide and ARN-509 while maintains sensitivity to first generation agents such as bicalutamide 
[36], [37] and [38]. 
Androgen receptor amplification/overexpression 
More than 80% of CRPC show high levels of AR expression because of gene amplification and/or 
overexpression [33] Preclinical studies showed that treatment with abiraterone is associated with a 3-fold 
increased expression of both full-length AR (FL AR) and truncated AR variants [29]. 
Enzalutamide resistant LNCaP cells express high levels of both FL AR and AR variants compared to CRPC 
LNCaP and knockdown of FL AR alone, or FL AR plus ARVs, induces apoptosis, suppresses cell growth and 
AR-regulated gene expression and delays tumor growth in vivo, suggesting that the AR is the key driver in 
the enzalutamide-resistant LNCaP model [39]. 
Androgen receptor splice variants (ARV) 
In several preclinical models, activation of the AR in the absence of ligand occurs with AR splice variants 
that lack the LBD remaining constitutively active as a transcription factor in a ligand-independent manner 
[40]. 
The most commonly expressed variants that drive PC progression under ADT conditions are ARV-7 and 
ARV-567 [41]. It is known that ARV levels are correlated with PC progression and that ARV expression 
significantly increases during ADT [16], [42], [43], [44] and [45]. 
In CRPC xenografts, both abiraterone and enzalutamide are associated with increased expression of 
truncated variants [29] and [39] and ARV expression can mediate resistance to therapies targeting FL AR, 
including enzalutamide. Metastatic CRPC cell lines expressing ARV show increased growth when exposed 
to enzalutamide and the selective knockdown of ARV expression inhibits androgen independent growth 
and restores responsiveness to androgens and antiandrogens [46]. 
Antonarakis et al. have recently isolated ARV-7 in circulating tumor cells from 31 enzalutamide-treated 
and 31 abiraterone-treated CRPC patients. ARV-7-positive patients had lower PSA response rates than 
ARV-7-negative both in patients treated with enzalutamide (0% vs 53%, p = 0.004) and in those treated 
with abiraterone (0% vs 68%, p = 0.004). Among patients receiving enzalutamide median clinical or 
radiographic PFS in ARV-7 positive group was 2.1 months compared to 6.1 months in the ARV-7 negative 
group (HR: 8.5; 95% CI: 2.8–25.5; p < 0.001). Similar results were obtained in patients receiving 
abiraterone (median PFS: 2.3 vs 6.3 months; HR 16.5; 95% CI: 3.3–82.9; p < 0.001). Moreover, ARV-7 was 
present in 9–15% of treatment-naive mCRPC patients but it increased during treatment with abiraterone 
(55%) or enzalutamide (50%), supporting the hypothesis that both intrinsic and acquired resistance to 
these agents may be associated with ARV-7 [47] and [48]. 
In a recent study Liu et al. identified niclosamide, an FDA-approved anthelminthic drug, as a potent ARV-7 
inhibitor in PC cells. Niclosamide significantly inhibited ARV-7 protein expression by protein degradation 
through a proteasome-dependent pathway and ARV-7 transcription activity and reduced ARV-7 
recruitment to the PSA promoter. Niclosamide inhibits in vitro PC cell growth and induces cell apoptosis 
and its combination with enzalutamide resulted in a significant inhibition of enzalutamide-resistant tumor 
growth, suggesting that niclosamide enhances enzalutamide activity and overcomes enzalutamide 
resistance in CRPC cells [49]. 
Glucocorticoid receptor overexpression 
Acquired resistance to enzalutamide and abiraterone can occur through an increased expression of 
glucocorticoid receptor (GR) that shares response elements with AR in multiple gene targets. 
Arora et al. identified that GR overexpression confers clinical resistance to enzalutamide [50]. GR is able to 
drive expression of certain AR target genes independent of AR and the GR agonist dexamethasone 
induced in vitro enzalutamide resistance whereas a GR antagonist restored sensitivity [50]. However, the 
prevalence and the clinical relevance of GR-driven CRPC are unknown. 
The progesterone receptor (PR) has been shown to be increased in CRPC and its two isoforms A and B are 
expressed in stromal fibroblast and smooth muscle cells of the prostate and are known to regulate cell 
proliferation. PR may be involved in resistance to enzalutamide and abiraterone due to continue 
progesterone production [51]. 
Activation of other pathways 
Parallel pathways have been also implicated in acquired resistance to abiraterone and enzalutamide, 
including EGFR-, Scr- and Pi3K pathway [52], [53] and [54], that may crosstalk with the AR pathway. 
Activation of Pi3K-AKT-mTOR signaling pathway is strongly implicated in prostate cancer progression 
[55] and [56] and this pathway contributes to PC development and progression though interaction with 
other critical pathways. In preclinical models Carver et al. demonstrated that AR and Pi3K signaling 
pathways are cross-regulated by reciprocal feedback. AR pathway inhibition results in a stronger 
activation of the Pi3K pathway, and may promote resistance to AR pathway inhibitors. Moreover Thomas 
et al. showed in vivo that synergistic targeting of Pi3K/AKT pathway and AR axis significantly delayed CRPC 
progression [57]. 
Another mechanism of resistance to enzalutamide is mediated by NF-kB2/p52 via activation of AR and its 
splice variants. Nadiminty et al. demonstrated that PC cells chronically treated with enzalutamide exhibit 
higher levels of NF-kB2/p52 and enhanced expression of ARV7 whereas expression of FL AR remained 
unchanged. Conversely in vitro down-regulation of NF-kB2/p52 in enzalutamide treated PC cells reduced 
ARVs expression and made cells more sensitive to enzalutamide [58]. 
Neuroendocrine transformation 
Neuroendocrine carcinoma of the prostate represents a subset of PC phenotypes that may be linked to 
resistance to AR signaling inhibition, aggressive tumor characteristics and poor prognosis. Recently, it was 
shown that treatment with enzalutamide may cause a reduced expression of the repressor element 1 
silencing transcription factor (REST), a mediator of AR action on gene repression that may be responsible 
of the neuroendocrine differentiation [59]. Neuroendocrine transformation may partly explain cross-
resistance between abiraterone and enzalutamide. 
Autophagy 
Autophagy is a tightly regulated catabolic process of cellular self-digestion by which cellular components 
are targeted to lysosomes for their degradation. Different forms of autophagy can be identified including 
macro-autophagy, micro-autophagy and chaperone-mediated autophagy. 
Macro-autophagy is associated with drug resistance in different types of cancer and can acts as an 
adaptive response to maintain cell survival under metabolic stresses, including androgen deprivation [60]. 
Recent studies suggested that autophagy has a pro-survival role in androgen-responsive cell lines LNCaP 
treated with androgen deprivation [61]. 
In a recent study Nguyen et al. showed that enzalutamide induces autophagy in androgen dependent 
CRPC cell lines by AMPK activation and mTOR suppression. Furthermore they demonstrated that small 
interfering RNA targeting AMPK significantly inhibited autophagy and promoted cell death in CaP cells 
treated with enzalutamide, suggesting that autophagy is an important survival mechanism in CRPC [62]. 
Finally, in vivo studies in orthotopically implanted mice with enzalutamide-resistant cells showed that the 
combination of enzalutamide and the autophagy modulators clomipramine or metformin significantly 
reduced tumor growth compared to control (p < 0.005) [62]. 
For chaperone-mediated autophagy, Matsumoto et al. reported that enzalutamide induced activation of 
clusterin, a cytoprotective chaperone, and clusterin knockdown synergically enhanced enzalutamide-
induced inhibition of LNCaP cell growth. The co-inhibition of the AR (with enzalutamide) and clusterin 
(with OGX-011) synergically enhanced apoptotic rates and delayed CRPC LNCaP tumor and PSA 
progression in vivo [63]. 
Immune evasion: PD-L1/PD-1 up-regulation 
Bishop et al. demonstrated in blood of patients progressing during treatment with enzalutamide a 
significant increase of PD-L1/2-positive dendritic cells (DC) compared to treatment naïve or responsive 
patients, and a correlation with treatment duration and poorer initial response to enzalutamide was also 
shown. These data are aligned with preclinical findings indicating increased amounts of circulating PD-
L1/2 + DC in mice with enzalutamide-resistant tumors compared to CRPC, and these resistant tumors also 
expressed significantly increased levels of tumor-intrinsic PD-L1 [64]. 
Discussion 
In the 1990s dedicated studies on AR in CRPC revealed escape mechanisms from androgen blockade 
through either mutation or amplification of AR [14]. Additionally, these resistance mechanisms 
corroborate the hypothesis that androgen-signaling remains biologically relevant despite castrate levels of 
testosterone and these observations guided the research and development of a new generation of 
androgen synthesis inhibitors and AR antagonists [4] and [5]. 
However, primary and acquired resistance to new hormonal agents approved for the treatment of CRPC is 
a complex phenomenon, not completely understood, involving AR signaling pathway and also dependant 
from AR bypassing mechanisms. In preclinical studies resistance to abiraterone and enzalutamide is 
mediated by similar mechanisms, including steroidogenesis up-regulation and AR overexpression (Table 2) 
[29]. 
Abiraterone induces androgen accumulation, such as pregnenolone and progesterone, upstream to the 
CYP17A1 enzymatic block. It has been demonstrated that mCRPC patients have an increased expression of 
PR [65] and that PR high density in PC cells is an independent poor prognostic factor [66]. PR and AR have 
88% sequence homology in the ligand-binding domain and share response elements in multiple gene 
targets [67]. As a consequence the progesterone binding to PR can induce transcription of androgen 
dependent genes. In a phase 1–2 study Jajaram et al. showed that progesterone receptor inhibition by 
onapristone, a progesterone receptor antagonist, in patients with CRPC progressed after abiraterone, 
enzalutamide or two lines of chemotherapy is feasible and safe [68]. This trial is ongoing and activity data 
are still pending (Table 3). 
Table 3.  
Proposed strategies to overcome abiraterone and/or enzalutamide mechanism of resistance and ongoing 
clinical trial. 
Mechanism of 
resistance 
How to overcome it 
Ongoing clinical 
trials 
• 
AR overexpression 
• 
Androgen 
biosynthesis 
pathway 
upregulation 
• 
Intracrine 
androgen 
synthesis 
Enzalutamide in combination with 
abiraterone acetate 
NCT01650194: 
Phase 2 
Increased-dose abiraterone 
acetate (2000 mg daily) 
NCT01637402: 
Phase 2 
ARN-509 + abiraterone 
NCT02123758: 
Phase 1 
ARN-509 + abiraterone 
NCT01792687: 
Phase 1 
ARN-509 + abiraterone 
NCT02257736: 
Phase 3 
Galeterone (AR antagonist and 
CYP17A1 inhibitor) 
NCT01709734: 
Phase 2 
Onapristone (progesterone 
receptor inhibitor) 
NCT02049190: 
Phase1/2 
• 
Immune evasion 
Pembrolizumab (anti PD-1) 
following Enzalutamide 
NCT02312557: 
Phase 2 
PROSTVAC (vaccine 
therapy) + enzalutamide 
NCT01867333 
• 
ARVs 
EPI-506 (NTD-binding AR 
antagonist) 
NCT: Pending 
FDA approval 
• 
Autophagy 
OGX-427 + abiraterone 
NCT01681433: 
Phase 2 
Alisertib (selective aurora A kinase NCT01848067: 
Mechanism of 
resistance 
How to overcome it 
Ongoing clinical 
trials 
induction inhibitor) + abiraterone Phase 1/2 
AT 13387 (HSP90 
inhibitor) + abiraterone 
NCT01685268: 
Phase 1/2 
• 
Activation of other 
pathways 
Crizotinib + enzalutamide 
NCT02207504: 
Phase 1 
Abiraterone + BEZ235 (Pi3K and 
mTOR inhibitor) or 
Abiraterone + BKM120 (Pi3K 
inhibitor) 
NCT01634061: 
Phase 1 
Dovitinib (multitargeted 
TKI) + Abiraterone 
NCT01994590: 
Phase 2 
Dasatibib (mutitargeted 
TKI) + abiraterone 
NCT01685125: 
Phase 2 
Olaparib (PARP-
inhibitor) + abiraterone 
NCT01972217: 
Phase 2 
Everolimus (m-TOR 
inhibitor) + ARN-509 (AR 
antagonist) 
NCT02106507: 
Phase 1 
BI 836845 (anti 
IGF1/IGF2) + enzalutamide 
NCT02204072: 
Phase 1 
Cabozantinib (anti c-MET and anti 
VEGFR2) + abiraterone 
NCT01574937: 
Phase 1 
• 
Other mechanisms 
Metformin + abiraterone 
NCT01677897: 
Phase 2 
Metformin + enzalutamide 
NCT02339168: 
Phase 1 
Cabazitaxel + abiraterone 
NCT02218606: 
Phase 2 
Table options 
Progesterone can also stimulate AR in presence of specific AR LBD mutations and can be converted to DHT 
via backdoor pathway [17]. 
Moreover, abiraterone does not completely block serum precursor steroids such as DHEA-S that can be 
transported and metabolized in cancer cells to DEA, a steroid downstream of CYP17A1, bypassing the 
enzymatic block induced by abiraterone [29]. 
When CYP17A1 is inhibited, 3β-hydroxysteroid dehydrogenase becomes the main enzyme involved in 
steroid synthesis. It is responsible of progesterone synthesis from pregnenolone, androstenedione 
synthesis from DHEA and TST synthesis from androstenediol (Fig. 1). In vitro studies showed that 
abiraterone, when administered at high dose, is able to inhibit both 3β-hydroxysteroid dehydrogenase 
activity and AR activity [31]. An ongoing trial is investigating higher vs standard doses of abiraterone for 
the treatment in CRPC patients (Table 3). 
The AR signaling pathway reactivation as resistance mechanism to abiraterone and increased androgen 
synthesis in patients treated with enzalutamide represent the biological background to test the 
combination of abiraterone with new generation AR antagonists, such as enzalutamide and ARN-509. An 
ongoing phase II study is administering simultaneously abiraterone and enzalutamide to CRPC patients 
with bone metastases. Preliminary results from this study indicate that the combination has a favorable 
safety profile and 48% of patients experienced PSA decline ⩾90% and 72% a PSA decline ⩾50% [69] (Table 
3). 
ARN-509 is a new AR antagonist that in xenograft models binds to AR with a superior potency than 
enzalutamide [70]. Several ongoing trials are evaluating the combination of abiraterone with 
enzalutamide or ARN-509 (Table 3). 
Sharing the same background, an ongoing phase III trial is investigating the efficacy of galeterone in 
chemotherapy-naïve CRPC patients (Table 2). Galeterone is an innovative hormonal agent that, at low 
concentrations, inhibits CYP17 activity, while at high concentrations induces AR degradation [71]. Due to 
its ability to induce AR degradation, galeterone could be active also in presence of AR splice variants. 
One of the most important resistance mechanisms is related to the detection of AR splicing variants and in 
presence of LBD loss of function NTD becomes the main AR domain, being crucial for transcriptional AR 
activity [40]. EPI-001 is a small molecule in preclinical development that binds the AR-transactivation 
domain of NTD causing the block of interaction of AR with AREs. In xenograft models EPI-001 
demonstrated efficacy in inhibiting the growth of CRPC models without causing toxicity [72]. The unique 
mechanism of action of this drug suggests that it can be active in presence of AR splicing variants. An 
ongoing phase 1–2 trial in men with enzalutamide and/or abiraterone-failure mCRPC, is evaluating the 
safety and antitumor activity of EPI-506, another NTD inhibitor. (Table 3). 
Resistance mechanisms to abiraterone and enzalutamide are peculiar and often different from those 
induced by chemotherapy. Recently Antonarakis assessed the correlation between the detection of ARV-7 
on circulating tumor cells and response in 37 CRPC patients treated with docetaxel or cabazitaxel. PSA 
response in ARV-7-positive and in ARV-7-negative patients was comparable (41% vs 65%, P = 0.19) as well 
as median PFS (5.1 vs 6.9 months, HR 2.65, P = 0.11) [48] and [73]. Taken together these data indicate that 
the combination of new hormonal agents with taxanes should be further investigated in the attempt to 
kill both ARV-7 positive and negative cancer cells and consequently to delay the onset of resistant clones 
[74]. Rationale for concomitant administration of new generation hormonal therapies and taxanes relies 
on advanced prostate carcinoma biology. Such disease, indeed, is heterogeneous with AR positive cells 
coexisting with cells not depending from AR pathway, the latter in principle sensitive to chemotherapy. 
Considering these biological basis and the above mentioned data it is reasonable to hypothesize that the 
concomitant administration of new hormonal agents and taxanes can be more advantageous in terms of 
outcome as compared to the sequential administration. An ongoing randomized phase II trial is assessing 
the combination of cabazitaxel and abiraterone in metastatic CRPC, compared to cabazitaxel alone, with 
progression-free survival after 3 months as primary endpoint (ClinicalTrials.gov Identifier NCT01845792). 
However, beside the risk of increased toxicity, it should be underlined that a combinatory approach has 
the potential risk to “spend” two effective agents in the same treatment line. A clinical trial adequately 
designed to compare the efficacy of the association of cabazitaxel and abiraterone or enzalutamide vs the 
sequential administration of those agents is warranted. In such a trial, comparing two different treatment 
strategies (combination vs sequential approach), the adequate endpoint would probably be overall 
survival, and not the progression-free survival of a single line of treatment. 
Heat shock proteins (HSPs) inhibitors represent another treatment opportunity to overcome acquired 
resistance to hormonal therapies. These agents are cytoprotective chaperones crucial for cytoplasmic AR 
stabilization [75]. In particular HSP27 acts as anti-apoptotic molecule and is overexpressed in CRPC 
patients while HSP90 promotes the ligand-independent nuclear translocation of AR [75]. A study of 
AT13387, a potent inhibitor of HSP90, in combination with abiraterone has recently been completed. 
Another phase II trial is assessing the efficacy of abiraterone in association with an HSP27 inhibitor OGX-
427 in CRPC patients with progressing levels of serum PSA (Table 3). 
There is a strong rationale to combine new generation hormonal therapies with biologic drugs. The 
inhibition of AR signaling activates several oncogenic pathways implicated in cancer cell survival, being the 
most important the Pi3K-AKT-mTOR and the MET signaling pathways. Initial trials are investigating the 
activity of abiraterone in combination with everolimus, an mTOR inhibitor, or BKM120, a Pi3K inhibitor 
and BEZ235 a dual Pi3K/mTOR inhibitor (Table 3). 
MET overexpression has been observed in primary and metastatic prostate carcinoma [76]. In xenograft 
models Verras et al. showed that castration induces c-Met expression and AR represses c-Met expression 
directly through binding to its promoter [77]. Cabozantinib is a small molecule kinase inhibitor with potent 
activity against MET and VEGFR2. Preliminary data of a phase 1 study showed that 20 or 40 mg of 
cabozantinib is feasible and safe when combined with Abiraterone [78]. The phase 2 trial testing the 
combination of cabozantinib and abiraterone was stopped after results of cabozantinib Phase 3 CRPC 
study XL184–307. Several ongoing trials are evaluating the combination of abiraterone or enzalutamide 
with agents acting on AR-independent pathways such as crizotinib, a mesenchymal-epithelial transition 
(MET)/ALK multi-targeted receptor tyrosine kinase inhibitor, dasatinib, a src inhibitor, dovitinib, a multi-
targeted receptor tyrosine kinase inhibitor, olaparib and veliparib, two PARP inhibitors. Alisertib, a 
selective aurora A kinase inhibitor and immunotherapies such as pembrolizumab (anti-PD1) and 
PROSTVAC (vaccine therapy) are other agent currently investigated in this setting (Table 3). 
Conclusion 
Although during the past decade specific molecular alterations have been identified in the so called 
“oncogene addicted” tumors that led to the development of specific and effective targeted therapies that 
induce tumor shrinkage in most of the treated cases as well as significantly extend progression-free 
survival, the responses to these agents is limited by the onset of acquired resistance. A deeper 
understanding of resistance mechanisms to these drugs is essential to maximize their efficacy and develop 
new strategies to overcome them. 
New generation hormonal therapies in CRPC, such as enzalutamide and abiraterone, have demonstrated 
also to prolong overall survival, but a proportion of patients do not benefit from these treatments and 
most patients develop resistance within a year. Primary and acquired resistance to abiraterone and 
enzalutamide depend from both AR-dependent or AR-independent mechanisms. Several novel agents, 
including new AR inhibitors, androgen synthesis inhibitors, HSP modulators, immunotherapies, tyrosine 
kinase inhibitors and others, are currently in clinical testing to prevent or overcome these resistance 
mechanisms. The combination of these drugs and hormonal therapies may synergically act to improve the 
clinical activity of systemic therapy in CRPC. 
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